CN116854689A - 一种咪唑[4,5f][1,10]邻菲啰啉类化合物及其制备方法和应用 - Google Patents
一种咪唑[4,5f][1,10]邻菲啰啉类化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN116854689A CN116854689A CN202311127783.5A CN202311127783A CN116854689A CN 116854689 A CN116854689 A CN 116854689A CN 202311127783 A CN202311127783 A CN 202311127783A CN 116854689 A CN116854689 A CN 116854689A
- Authority
- CN
- China
- Prior art keywords
- acid
- compound
- pharmaceutically acceptable
- phenanthroline
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title claims abstract description 50
- -1 [1,10] phenanthroline compound Chemical class 0.000 title claims description 33
- 238000002360 preparation method Methods 0.000 title claims description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 38
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- 238000010357 RNA editing Methods 0.000 claims abstract description 8
- 230000026279 RNA modification Effects 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 108091081406 G-quadruplex Proteins 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 10
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 9
- 229960000583 acetic acid Drugs 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 7
- KCALAFIVPCAXJI-UHFFFAOYSA-N 1,10-phenanthroline-5,6-dione Chemical compound C1=CC=C2C(=O)C(=O)C3=CC=CN=C3C2=N1 KCALAFIVPCAXJI-UHFFFAOYSA-N 0.000 claims description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 6
- 239000005695 Ammonium acetate Substances 0.000 claims description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 229940043376 ammonium acetate Drugs 0.000 claims description 6
- 235000019257 ammonium acetate Nutrition 0.000 claims description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 6
- 239000012362 glacial acetic acid Substances 0.000 claims description 6
- 239000005457 ice water Substances 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 150000007522 mineralic acids Chemical class 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 230000000259 anti-tumor effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 3
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 claims description 3
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 claims description 3
- 229930016911 cinnamic acid Natural products 0.000 claims description 3
- 235000013985 cinnamic acid Nutrition 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 3
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 3
- QENGPZGAWFQWCZ-UHFFFAOYSA-N Methylthiophene Natural products CC=1C=CSC=1 QENGPZGAWFQWCZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 abstract description 36
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract description 8
- 201000002528 pancreatic cancer Diseases 0.000 abstract description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract description 8
- 238000013519 translation Methods 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 abstract description 3
- 206010006187 Breast cancer Diseases 0.000 abstract description 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 2
- 206010009944 Colon cancer Diseases 0.000 abstract description 2
- 208000032612 Glial tumor Diseases 0.000 abstract description 2
- 206010018338 Glioma Diseases 0.000 abstract description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 2
- 208000034578 Multiple myelomas Diseases 0.000 abstract description 2
- 206010033128 Ovarian cancer Diseases 0.000 abstract description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract description 2
- 206010060862 Prostate cancer Diseases 0.000 abstract description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 abstract description 2
- 206010057644 Testis cancer Diseases 0.000 abstract description 2
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 2
- 206010017758 gastric cancer Diseases 0.000 abstract description 2
- 201000005787 hematologic cancer Diseases 0.000 abstract description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract description 2
- 208000032839 leukemia Diseases 0.000 abstract description 2
- 201000007270 liver cancer Diseases 0.000 abstract description 2
- 208000014018 liver neoplasm Diseases 0.000 abstract description 2
- 201000005202 lung cancer Diseases 0.000 abstract description 2
- 208000020816 lung neoplasm Diseases 0.000 abstract description 2
- 201000001441 melanoma Diseases 0.000 abstract description 2
- 201000011549 stomach cancer Diseases 0.000 abstract description 2
- 201000003120 testicular cancer Diseases 0.000 abstract description 2
- 210000004881 tumor cell Anatomy 0.000 abstract description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 abstract 1
- 201000007983 brain glioma Diseases 0.000 abstract 1
- 208000010916 pituitary tumor Diseases 0.000 abstract 1
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical class C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 1
- BIYGAOBOLDXNHM-UHFFFAOYSA-N 1-ethylsulfonylpiperazine Chemical compound CCS(=O)(=O)N1CCNCC1 BIYGAOBOLDXNHM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000001768 microscale thermophoresis Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- VUAOIXANWIFYCU-UHFFFAOYSA-N quinoline-6-carbaldehyde Chemical compound N1=CC=CC2=CC(C=O)=CC=C21 VUAOIXANWIFYCU-UHFFFAOYSA-N 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种咪唑[4,5f][1,10]邻菲啰啉类化合物及其制备方法和应用，该化合物选自结构式如式A‑2或式A‑4所示的化合物，本发明还公开了上述化合物对RNA编辑酶ADAR1的翻译有明显的抑制作用,该类化合物可抑制多种肿瘤细胞的增殖，包括胰腺癌、肺癌、胃癌、前列腺癌、卵巢癌、睾丸癌、结肠癌、白血病、乳腺癌、多发性骨髓瘤、肝癌、黑色素瘤、神经胶质瘤、脑胶质瘤、脑垂体瘤等多种实体瘤和血液瘤。本发明为肿瘤治疗提供一项选择。
Description
技术领域
本发明涉及一种化合物及其制备方法和应用，具体地，涉及一种咪唑[4,5f][1,10]邻菲啰啉类化合物及其制备方法和应用。
背景技术
RNA编辑是最常见的转录后修饰之一，它增加了转录物的多样性和基因调控机制，在肿瘤的发生和发展中发挥着重要作用。作用于RNA的腺苷脱氨酶（ADARs）是RNA编辑酶家族的成员。ADARs催化腺苷在双链RNA（dsRNA）中转录后转化为肌苷，导致其序列、编码潜力和二级结构发生变化。ADAR1是ADARs家族的成员，是研究最广泛的RNA编辑酶，具有两种异构体，干扰素（IFN）诱导的全长ADAR1-p150和较短的ADAR1-p110。ADAR1的表达和活性升高与多种癌症和病毒感染的进展密切相关，包括严重急性呼吸系统综合征冠状病毒的感染和进化。肿瘤中ADAR1的缺失不仅导致许多肿瘤细胞系的增殖减少和细胞凋亡增加，而且克服了对免疫检查点阻断的抵抗。因此，抑制ADAR1功能是许多癌症的可行治疗策略。
G-quadruplex (G-四联体)是由堆叠鸟嘌呤(G)通过Hoogsteen氢键组成的DNA或RNA二级结构。特定的离子强度下能够折叠形成G-四链体结构。由于 G-四联体平面的堆积，在中轴方向形成了一个极性的中央空腔，这个空腔可以螯合适当体积的阳离子，从而增强G-四链体结构的稳定性。5’非翻译区(5’UTR)中的RNA G-四链体(rG4)结构在基本细胞过程中发挥着至关重要的作用。ADAR1是一种与双链RNA结合的重要酶，负责在RNA编辑中将腺苷转化为肌苷，rG4在控制ADAR1翻译中发挥着关键作用。稳定rG4可以抑制ADAR1的翻译，从而达到抗肿瘤或抗病毒的功能。
胰腺癌是一种高度致命的恶性肿瘤，被誉为“癌中之王”，其5年生存率仅约10%。研究表明，高表达的ADAR1与胰腺癌的不良预后相关。目前，关于ADAR1的特异性抑制剂的研究很少，并无靶向ADAR1的小分子公认药物在临床研究报道，并且尚无ADAR1的G四联体稳定剂报道。因此，开发ADAR1 rG4稳定剂用于胰腺癌和其他癌症的治疗是必要的。
发明内容
发明目的：本发明的目的是提供一种咪唑[4,5f][1,10]邻菲啰啉类化合物或其药学上可接受的盐，针对并稳定G四联体发挥强效抗肿瘤活性，可以有效克服因ADAR1抑制剂开发难的问题，为针对ADAR1的药物开发提供新的化合物；本发明的另一目的是提供一种咪唑[4,5f][1,10]邻菲啰啉类化合物或其药学上可接受的盐的制备方法；本发明的另一目的是提供一种药物组合物；本发明的另一目的是提供一种咪唑[4,5f][1,10]邻菲啰啉类化合物或其药学上可接受的盐在制备用于预防和/或治疗癌症或肿瘤以及病毒感染相关疾病的药物中的应用。
技术方案：本发明的一种咪唑[4,5f][1,10]邻菲啰啉类化合物或其药学上可接受的盐，该化合物为如式A-2或式A-4所示的化合物：。
进一步地，所述药学上可接受的盐为如式A-2或式A-4所示的化合物的酸加成盐，其中用于成盐的酸包括无机酸及有机酸。
更进一步地，所述无机酸为盐酸、硫酸、磷酸或有机酸；有机酸为乙酸、三氯乙酸、三氟乙酸、丙酸、丁酸、马来酸、对甲苯磺酸、苹果酸、甲磺酸、丙二酸、肉桂酸、柠檬酸、富马酸、樟脑酸、二葡糖酸、天冬氨酸或酒石酸。
另一方面，本发明提供一种咪唑[4,5f][1,10]邻菲啰啉类化合物或其药学上可接受的盐的制备方法，如式A-2所示的化合物由以下步骤制备：
将1,10-邻二氮杂菲-5,6-二酮和3-甲基噻吩醛溶于冰醋酸中，加入醋酸铵，反应一段时间，反应完毕后，倒入冰水中，氨水调pH值至中性，析出固体为目标产物。
优选地，上述制备中，反应温度为120℃，反应时间为6小时。
进一步地，如式A-4所示的化合物由以下步骤制备：
将1,10-邻二氮杂菲-5,6-二酮和2,6-二氯-3-吡啶甲醛溶于冰醋酸中，加入醋酸铵，反应一段时间，反应完毕后，倒入冰水中，氨水调pH值至中性，析出固体为目标产物。
优选地，上述制备中，反应温度为120℃，反应时间为6小时。
另一方面，本发明提供一种药物组合物，所述药物组合物包含上述的咪唑[4,5f][1,10]邻菲啰啉类化合物或其药学上可接受的盐，以及药学上可接受的载体。
药学上可接受的载体指的是对有机体不引起明显的刺激性和不干扰所给予化合物的生物活性和性质的赋形剂或稀释剂。所述赋形剂包括矫味剂、芳香剂、助溶剂、乳化剂、增溶剂、黏合剂、防腐剂、抗氧剂、渗透压调节剂、着色剂填充剂、崩解剂、润滑剂等，所述稀释剂包括淀粉、生理盐水、蔗糖、乳糖、糊精等。
另一方面，本发明提供一种咪唑[4,5f][1,10]邻菲啰啉类化合物或其药学上可接受的盐在制备用于预防和/或治疗癌症或肿瘤以及病毒感染相关疾病的药物中的应用。
优选地，所述癌症或肿瘤相关疾病包括胰腺癌、肺癌、胃癌、前列腺癌、卵巢癌、睾丸癌、结肠癌、白血病、乳腺癌、多发性骨髓瘤、肝癌、黑色素瘤、神经胶质瘤、脑胶质瘤、脑垂体瘤多种实体瘤和血液瘤。
进一步地，咪唑[4,5f][1,10]邻菲啰啉类化合物或其药学上可接受的盐发挥抗肿瘤活性的靶点为G四联体。
在其中一些实施例中，所述G四联体来源于RNA编辑酶ADAR1、肝细胞生长因子受体(c-Met)以及原癌基因c-Myc。
本发明所述的通式（I）化合物或其药学上可接受的盐，对于RNA编辑酶ADAR1的翻译具有抑制活性，对相关恶性肿瘤具有治疗效果。
本发明中的术语除特别说明外，一般具有如下的含义：
术语“烷基”表示具有所述数目碳原子的直链或支链饱和烃基。
术语“C1-C4烷基”是指具有1-4个碳原子的直链或支链饱和烃基；C1-C4烷基包括但不限于甲基、乙基、正丙基、异丙基、正丁基等。卤代C1-C4烷基是指烷基链有一个及以上卤素取代的C1-C4烷基。
术语“环烷基”表示具有环状结构的烷基，包括但不限于环丙基，环丁基，环戊基、环己基等。
术语“烷氧基”表示末端含有一个氧原子的烷基，包括但不限于甲氧基，乙氧基，正丙氧基，异丙氧基。
术语“卤素”为氟、氯、溴或碘；优选为氟、氯、溴。
术语“杂环”包括饱和和不饱和的多元含氮杂环，包括但不限于环乙胺，环丙胺，吗啉，哌嗪，吡嗪，吡咯，四氢吡咯，咪唑，N-甲基哌嗪，N-乙基哌嗪，N-乙磺酰基哌嗪等。
有益效果：与现有技术相比，本发明具有如下显著优点：高表达的ADAR1与胰腺癌的不良预后相关。目前，关于ADAR1的特异性抑制剂的研究很少，并且尚无ADAR1 G四联体（ADAR1-G4s）化合物报道。因此，本发明制备的咪唑[4,5f][1,10]邻菲啰啉类化合物可以稳定ADAR1 rG4，抑制ADAR1的翻译，对胰腺癌和其他癌症治疗具有显著抗增殖活性。此外，针对ADAR1的G四联体来抑制ADAR1的表达从而发挥抗肿瘤的生物学功能，可以克服ADAR1小分子抑制剂开发难度大的问题。
附图说明
图1为化合物A-4调控ADAR1的蛋白水平结果图；
图2为化合物A-4调控mRNA水平结果图；
图3为MST测定化合物A-4与ADAR-G4s的结合能力图。
实施方式
下面对本发明作进一步描述。以下实施例仅用于更加清楚地说明本发明的技术方案，而不能以此来限制本发明的保护范围。下述实施例中的实验方法，如无特殊说明，均为常规方法。下述实施例中所用的试验材料，如无特殊说明，均为自常规生化试剂商店购买得到的。
本发明实施例提供一种具有如通式（I）所示的化合物，或其药学上可接受的盐：
R选自取代的五元芳杂环、取代的六元芳环或六元芳杂环、取代的并环。
其中，所述药学上可接受的盐为通式（I）化合物的酸加成盐，其中用于成盐的酸包括无机酸及有机酸，所述无机酸包括盐酸、硫酸、磷酸，有机酸包括乙酸、三氯乙酸、三氟乙酸、丙酸、丁酸、马来酸、对甲苯磺酸、苹果酸、甲磺酸、丙二酸、肉桂酸、柠檬酸、富马酸、樟脑酸、二葡糖酸、天冬氨酸和酒石酸。
本发明实施例提供一种上述化合物的制备方法，包括以下步骤：
将1,10-邻二氮杂菲-5,6-二酮和相应的醛溶于冰醋酸中，加入醋酸铵，反应一段时间，反应完毕后，倒入冰水中，氨水调pH值至中性，析出固体为目标产物。
本发明实施例涉及的具体化合物如下：
下面结合具体实施例对本申请做出详细说明。
一、化合物A-1—A-4的合成
实施例1
2-（喹啉-6-基）-1H-咪唑并[4,5-f][1,10]菲咯啉（A-1）的合成：
将1,10-邻二氮杂菲-5,6-二酮(1eq, 1 mmol)和喹啉-6-甲醛(1eq, 1 mmol)溶于冰醋酸中，加入醋酸铵，于120 ℃反应6小时，反应完毕后，倒入冰水中，氨水调pH值至中性，析出固体为A-1,收率80%。1H NMR (300 MHz, DMSO-d 6) δ 9.06 (dd,J= 4.3, 1.8 Hz,2H), 9.03 – 8.93 (m, 3H), 8.89 (d,J= 2.0 Hz, 1H), 8.70 (dd,J= 8.8, 2.0 Hz,1H), 8.57 (dd,J= 8.5, 1.8 Hz, 1H), 8.24 (d,J= 8.9 Hz, 1H), 7.87 (dd,J= 8.1,4.3 Hz, 2H), 7.65 (dd,J= 8.3, 4.2 Hz, 1H)。
实施例2
2-（3-甲基噻吩-2-基）-1H-咪唑并[4,5-f][1,10]菲咯啉（A-2）的合成：
参照A-1的合成方法，浅黄色固体，产率83%。1H NMR (300 MHz, DMSO-d 6) δ 13.56(s, 1H), 9.09 – 8.81 (m, 4H), 7.84 (s, 2H), 7.70 (d,J= 5.0 Hz, 1H), 7.14 (d,J= 5.0 Hz, 1H), 2.70 (s, 3H)。
实施例3
2-（1H-吲哚-3-基）-1H模拟物[4,5-f][1,10]菲咯啉（A-3）的合成：
参照A-1的合成方法，浅黄色固体，产率60%。1H NMR (400 MHz, DMSO-d 6) δ 13.40(s, 1H), 11.70 (d,J= 2.7 Hz, 1H), 9.03 (td,J= 5.8, 5.2, 3.3 Hz, 3H), 8.85(dd,J= 8.2, 1.8 Hz, 1H), 8.72 – 8.65 (m, 1H), 8.23 (d,J= 2.7 Hz, 1H), 7.85(ddd,J= 10.2, 8.1, 4.3 Hz, 2H), 7.58 – 7.52 (m, 1H), 7.30 – 7.23 (m, 2H)。
实施例4
2-（2,6-二氯吡啶-3-基）-1H-咪唑并[4,5-f][1,10]菲咯啉（A-4）的合成：
参照A-1的合成方法，浅黄色固体，产率75%。1H NMR (400 MHz, DMSO-d 6) δ 9.06(dd,J= 4.4, 1.7 Hz, 2H), 8.89 (dd,J= 8.1, 1.8 Hz, 2H), 8.50 (d,J= 8.1 Hz,1H), 7.92 – 7.76 (m, 3H)。
二、生物学评价实验：
（1）、ADAR1蛋白水平检测：
将对数生长期细胞以4×105- 5×105cells/孔接种于6孔板，置于37°C，5% CO2条件下培养12-24小时；向培养板加入梯度稀释的不同浓度的待测化合物溶液100 μL，将培养板在37 °C，5% CO2培养箱条件下孵育24小时；孵育结束后收集细胞，1200 rpm离心3分钟，PBS洗涤两次，1 mL PBS重悬细胞，转移至1.5 mL离心管2500 rcf离心5分钟；小心弃去上清，加入细胞裂解液和蛋白酶抑制剂及磷酸酶抑制剂，摇匀15分钟，4 °C 1400 rcf离心15分钟收集上清测定蛋白浓度用于后续Western-Blotting检测。
从图1可以看出，本发明实施例化合物A-4可以显著抑制ADAR1蛋白的表达。
（2）、ADAR1 mRNA水平检测：
将对数生长期细胞以4×105- 5×105cells/孔接种于6孔板，置于37°C，5% CO2条件下培养12-24小时；向培养板加入梯度稀释的不同浓度的待测化合物溶液100 μL，将培养板在37 °C，5% CO2培养箱条件下孵育24小时；孵育结束后收集细胞，1200 rpm离心3分钟，PBS洗涤两次，1 mL PBS重悬细胞，转移至1.5 mL离心管2500 rcf离心5分钟；小心弃去上清，加入RNA-easy试剂500 μL吹打至细胞充分裂解，加入200 μL RNA-free双蒸水混匀，静置5分钟；取上清650 μL加入等体积异丙醇颠倒混匀，-20 °C静置30分钟；12000 rcf离心，弃去上清，加入500 μL 75%乙醇洗涤两次，8000 rcf离心3分钟，吸走上清，风干；加入30 μLRNA-free双蒸水充分溶解，-80 °C保存；所得RNA样品在测完浓度后用于后续的PCR实验。
从图2可以看出，本发明实施例化合物A-4并不影响ADAR1 mRNA的水平，结合之前WB结果，表明本发明实施例化合物A-4只影响翻译水平而不影响转录水平。
（3）、微量热泳动法（Microscale thermophoresis，MST）测试化合物与ADAR1 rG4的结合能力：
实验材料：
毛细管：MO-K022 MonolithNT.115 Capillaries Lot:899917；
缓冲液：Folding Buffer：pH 7.5,50mM HEPES，100mM KCl，10mM MgCl2，0.005%Tween-20；
RNA：
用缓冲液配制浓度为2 μM的RNA溶液，于95oC加热3分钟，并缓慢冷却至室温。用缓冲液配制25 μM的化合物，并从25μM开始向下倍比稀释15个浓度梯度。在室温条件下，将化合物与G4-RNA 1:1混合混匀，并避光孵育20分钟。孵育完成后，用MO-K022玻璃毛细管按顺序吸取混合物于样品架，用MO.Affinity软件检测。采用MO.Affinity Analysisv 2.2.4软件（Nano TemperTechnologies）进行数据处理。
从图3可以看出，本发明实施例化合物A-4对ADAR1 rG4的结合能力较强，其Kd值为0.287 ± 0.093 μM。
（4）、体外细胞活性测定：
按照CCK-8法进行测定化合物对多种癌细胞增殖的抑制作用，并得出化合物抑制细胞增殖活性的半数抑制浓度IC50值。将对数生长期细胞以3000-5000 cells/孔接种于96孔板，置于37°C，5% CO2条件下培养12-24小时；向培养板加入梯度稀释的不同浓度的待测化合物溶液100 μL，将培养板在37 °C，5% CO2培养箱条件下孵育72小时；孵育结束前4 h，每孔加入10 μL CCK-8溶液（5 mg/mL）。孵育结束后，用酶标仪测定OD450，抑制率=（对照组OD值－实验组OD值）/对照组OD值×100%；得出数据后，GraphPad Prism 拟合得出IC50。其中个化合物的IC50:
表1、本发明化合物对胰腺癌细胞系PANC-1的抗增殖活性
| A-1 | A-2 | A-3 | A-4 | |
| IC50(μM) | 3.64 | 0.32 | 6.68 | 0.22 |
根据实验结果可以得出，本发明实施例的化合物对胰腺癌细胞系有着强效的抗增殖活性。
Claims (6)
1.一种咪唑[4,5f][1,10]邻菲啰啉类化合物或其药学上可接受的盐，其特征在于，该化合物为结构式如式A-2或式A-4所示的化合物：。
2.根据权利要求1所述的咪唑[4,5f][1,10]邻菲啰啉类化合物或其药学上可接受的盐，其特征在于，所述药学上可接受的盐为如式A-2或式A-4所示的化合物的酸加成盐，其中用于成盐的酸包括无机酸及有机酸。
3.根据权利要求2所述的咪唑[4,5f][1,10]邻菲啰啉类化合物或其药学上可接受的盐，其特征在于，所述无机酸为盐酸、硫酸或磷酸；有机酸为乙酸、三氯乙酸、三氟乙酸、丙酸、丁酸、马来酸、对甲苯磺酸、苹果酸、甲磺酸、丙二酸、肉桂酸、柠檬酸、富马酸、樟脑酸、二葡糖酸、天冬氨酸或酒石酸。
4.一种根据权利要求1-3中任一项所述的咪唑[4,5f][1,10]邻菲啰啉类化合物或其药学上可接受的盐的制备方法，其特征在于，如式A-2所示的化合物由以下步骤制备：
将1,10-邻二氮杂菲-5,6-二酮和3-甲基噻吩醛溶于冰醋酸中，加入醋酸铵，反应一段时间，反应完毕后，倒入冰水中，氨水调pH值至中性，析出固体为目标产物；
如式A-4所示的化合物由以下步骤制备：
将1,10-邻二氮杂菲-5,6-二酮和2,6-二氯-3-吡啶甲醛溶于冰醋酸中，加入醋酸铵，反应一段时间，反应完毕后，倒入冰水中，氨水调pH值至中性，析出固体为目标产物。
5.一种药物组合物，其特征在于，所述药物组合物包含根据权利要求1-3中任一项所述的咪唑[4,5f][1,10]邻菲啰啉类化合物或其药学上可接受的盐，以及药学上可接受的载体。
6.一种根据权利要求1-3中任一项所述的咪唑[4,5f][1,10]邻菲啰啉类化合物或其药学上可接受的盐在制备用于预防和/或治疗癌症或肿瘤以及病毒感染相关疾病的药物中的应用；咪唑[4,5f][1,10]邻菲啰啉类化合物或其药学上可接受的盐发挥抗肿瘤活性的靶点为G四联体；所述G四联体来源于RNA编辑酶ADAR1的mRNA。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311127783.5A CN116854689B (zh) | 2023-09-04 | 2023-09-04 | 一种咪唑[4,5f][1,10]邻菲啰啉类化合物及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311127783.5A CN116854689B (zh) | 2023-09-04 | 2023-09-04 | 一种咪唑[4,5f][1,10]邻菲啰啉类化合物及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116854689A true CN116854689A (zh) | 2023-10-10 |
| CN116854689B CN116854689B (zh) | 2023-11-17 |
Family
ID=88221974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311127783.5A Active CN116854689B (zh) | 2023-09-04 | 2023-09-04 | 一种咪唑[4,5f][1,10]邻菲啰啉类化合物及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116854689B (zh) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101220293A (zh) * | 2007-09-26 | 2008-07-16 | 江苏大学 | 离子液体萃取-催化氧化脱硫的方法 |
| CN101595084A (zh) * | 2006-06-29 | 2009-12-02 | 金克斯医药品有限公司 | 用于调整激酶级联的二芳基组合物和方法 |
| CN102491987A (zh) * | 2011-12-13 | 2012-06-13 | 武汉纺织大学 | 一种邻菲啰啉功能化氮杂环卡宾四核铜化合物及其制备方法 |
| CN103896848A (zh) * | 2014-04-11 | 2014-07-02 | 中国农业科学院茶叶研究所 | 一种具咪唑环结构大位阻双炔化合物的制备方法 |
| CN106336400A (zh) * | 2008-12-08 | 2017-01-18 | 萌蒂制药国际有限公司 | 酪氨酸激酶蛋白受体拮抗剂 |
| CN106588999A (zh) * | 2016-11-25 | 2017-04-26 | 玉林师范学院 | 一种肝癌细胞抑制剂及其制备方法 |
| CN110746423A (zh) * | 2019-11-11 | 2020-02-04 | 福建医科大学 | 芳基咪唑并菲啰啉荧光染料的合成及对金属离子的识别 |
-
2023
- 2023-09-04 CN CN202311127783.5A patent/CN116854689B/zh active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101595084A (zh) * | 2006-06-29 | 2009-12-02 | 金克斯医药品有限公司 | 用于调整激酶级联的二芳基组合物和方法 |
| CN101220293A (zh) * | 2007-09-26 | 2008-07-16 | 江苏大学 | 离子液体萃取-催化氧化脱硫的方法 |
| CN106336400A (zh) * | 2008-12-08 | 2017-01-18 | 萌蒂制药国际有限公司 | 酪氨酸激酶蛋白受体拮抗剂 |
| CN102491987A (zh) * | 2011-12-13 | 2012-06-13 | 武汉纺织大学 | 一种邻菲啰啉功能化氮杂环卡宾四核铜化合物及其制备方法 |
| CN103896848A (zh) * | 2014-04-11 | 2014-07-02 | 中国农业科学院茶叶研究所 | 一种具咪唑环结构大位阻双炔化合物的制备方法 |
| CN106588999A (zh) * | 2016-11-25 | 2017-04-26 | 玉林师范学院 | 一种肝癌细胞抑制剂及其制备方法 |
| CN110746423A (zh) * | 2019-11-11 | 2020-02-04 | 福建医科大学 | 芳基咪唑并菲啰啉荧光染料的合成及对金属离子的识别 |
Non-Patent Citations (4)
| Title |
|---|
| FANG, HSIAO-PING: ""Synthesis and study of novel supramolecular nanocomposites containing aryl-imidazo-phenanthroline-based metallo-polymers (H-donors) and surface-modified ZnO nanoparticles (H-acceptors)"", 《TETRAHEDRON》, vol. 69, no. 1, pages 293 - 301 * |
| SCHNEIDER, KILIAN R. A.: ""Intracellular Photophysics of an Osmium Complex bearing an Oligothiophene Extended Ligand"", 《CHEMISTRY - A EUROPEAN JOURNAL》, vol. 26, no. 65, pages 14844 - 14851 * |
| YU-XIN PENG, ET AL: ""Simultaneous enhancement of fluorescence and solubility by N-alkylation and functionalization of 2-(2-thienyl)imidazo[4, 5-f][1, 10]-phenanthroline with heterocyclic bridges"", 《RCS ADVANCES》, vol. 9, pages 284 - 285 * |
| 闵文剑: ""新型降血脂药物的研究进展"", 《中国新药杂志》, vol. 28, no. 19, pages 2368 - 2374 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116854689B (zh) | 2023-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102288281B1 (ko) | Fgfr4 억제제, 이의 제조 방법 및 약학적 응용 | |
| AU2016272057B2 (en) | Use of pteridinone derivative serving as EGFR inhibitor | |
| EP2896620A1 (en) | Alkynyl heteroaromatic ring compound and application thereof | |
| JP2001515078A (ja) | プロテインチロシンキナーゼおよび細胞周期キナーゼ仲介細胞増殖を阻害するためのナフチリジノン | |
| KR20090086219A (ko) | 이미다조[1,2-ｂ]피리다진 및 피라졸로[1,5-ａ]피리미딘 유도체 및 단백질 키나제 억제제로서의 이의 용도 | |
| CN102659765A (zh) | 嘧啶及三嗪类化合物的制备方法和应用 | |
| CN111989332B (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| CN113683616A (zh) | Kras g12c突变蛋白抑制剂 | |
| CN108101926B (zh) | 含喹啉酮的嘧啶并五元杂环类化合物、制备方法及其应用 | |
| CN112300154B (zh) | 一类含氮杂环化合物、其制备方法和用途 | |
| US20240294528A1 (en) | Prmt5 inhibitors and methods of use | |
| CN116854689B (zh) | 一种咪唑[4,5f][1,10]邻菲啰啉类化合物及其制备方法和应用 | |
| CN116782903A (zh) | 取代的吡啶酮化合物及应用 | |
| CN110885332B (zh) | 一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用 | |
| CN109369656B (zh) | 喹啉类化合物硫酸盐的晶型、制备方法、组合物与应用 | |
| CN116425751B (zh) | 作为mat2a抑制剂的多环类化合物 | |
| US20090054471A1 (en) | Pyridopyrazolopyrimidine compounds and their uses as anti-cancer and anti-diabete drugs | |
| CN114409636B (zh) | 一种喹唑啉酮化合物或其药学上可接受的盐及其制备方法和应用 | |
| CN111662271B (zh) | 具有idh突变体抑制活性的化合物及其制备方法与应用 | |
| TW201738227A (zh) | 一種稠環化合物、其製備方法和應用及其中間體化合物 | |
| CN113527306A (zh) | 喹啉类TGF-β1抑制剂的晶型 | |
| CN111808079A (zh) | 吲哚类ask1小分子抑制剂及其制备方法和应用 | |
| CN107964012B (zh) | 作为parp抑制剂的化合物及其用途 | |
| KR20210123314A (ko) | 불소 함유 치환 벤조티오펜 화합물, 그의 약학적 조성물 및 응용 | |
| WO2023131305A1 (zh) | Prmt5抑制剂和抗癌治疗剂的组合 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |